Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
Status:
Recruiting
Trial end date:
2025-04-28
Target enrollment:
Participant gender:
Summary
This is an open label pilot study designed to provide access to treatment with
investigational convalescent plasma and assess the relationship between NAb titers in the
investigational convalescent plasma compared to changes in NAb levels in the recipient in
hospitalized patients with COVID-19.